Overview

Intravitreal Ozurdex After Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy

Status:
Unknown status
Trial end date:
2015-09-01
Target enrollment:
0
Participant gender:
All
Summary
To evaluate if intravitreal Ozurdex can reduce the incidence of recurrent vitreous hemorrhage after primary pars plana vitrectomy (PPV) in patients with proliferative diabetic retinopathy (PDRP).
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Anders Kvanta
Treatments:
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Criteria
Inclusion Criteria:

- Patients with vitreous hemorrhage undergoing PPV for PDRP

Exclusion Criteria:

- Previous PPV

- Vitreous hemorrhage of non-PDRP origin